norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

•There is an urgent need for novel drugs for PSC.•In this phase II clinical trial, norUDCA reduced serum ALP levels within 12 weeks.•norUDCA’s effects on liver enzymes were dose-dependent.•The safety profile of norUDCA was excellent. Background & AimPrimary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23...